Research programme: oral cancer vaccines - UbiVac/Janssen Biotech
Alternative Names: Oral cancer vaccine - UbiVac/Janssen BiotechLatest Information Update: 28 Oct 2019
Price :
$50 *
At a glance
- Originator UbiVac
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Orofacial cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Orofacial-cancer in USA (Intralymphatic, Injection)
- 29 Sep 2015 UbiVac and Janssen Biotech collaborate to develop a vaccine for Orofacial cancer in USA
- 29 Sep 2015 Preclinical trials in Orofacial cancer in USA (unspecified route)